Affinity-matured CD72-targeting nanobody CAR T cells enhance elimination of antigen-low B-cell malignancies
Open Access
- 30 December 2025
- journal article
- Published by BMJ in Journal for ImmunoTherapy of Cancer
- Vol. 13 (12) , e012013
Abstract
Background: Chimeric antigen receptor (CAR) T-cell therapies are highly efficacious for several different hematologic cancers. However, for most CAR T targets it is observed that low surface antigen density on tumors can significantly reduce therapeutic efficacy. In this study, we explore this dynamic in the context of CD72, a surface antigen we recently found as a promising target for refractory B-cell cancers, but for which CD72 low antigen density can lead to therapeutic resistance in preclinical models. Methods: Primary samples were accessed via institutional review board-approved protocols. Affinity-matured and humanized nanobody clones were previously described in Temple et al. (2023). CAR T cells were generated via lentiviral transduction. In vitro cytotoxicity assays were performed using luciferase-labeled cell lines. In vivo studies were performed using cell line-derived or patient-derived xenografts implanted in NOD scid gamma mice. Results: We first confirmed ubiquitous CD72 expression across a range of primary B-cell non-Hodgkin lymphomas. We further found that after resistance to CD19-directed therapies, across both B-cell acute lymphoblastic leukemia (B-ALL) models and primary tumor samples, surface CD72 expression was largely preserved while CD22 expression was significantly diminished. Affinity maturation of a nanobody targeting CD72, when incorporated into CAR T cells, led to more effective elimination in vitro of isogenic models of CD72 low-expressing tumors. These results suggested that nanobody-based CAR T cells (nanoCARs) may exhibit a similar relationship between binder affinity, antigen expression, and efficacy as previously demonstrated only for single chain variable fragment-based CAR T cells. Surprisingly, however, this significantly improved in vitro efficacy only translated to modest in vivo survival benefit. As a parallel strategy to enhance CAR T function, we found that the small molecule bryostatin could also significantly increase CD72 surface antigen density on B-cell malignancy models. Structural modeling and biochemical analysis identified critical residues improving CD72 antigen recognition of our lead affinity-matured nanobody. Conclusions: Together, these findings support affinity-matured CD72 nanoCARs as a potential immunotherapy product for CD19-refractory B-cell cancers. Our results also suggest that for B-ALL in particular, CD72 may be a preferable second-line immunotherapy target over CD22.Keywords
All Related Versions
Funding Information
- Intramural Research Program, Center of Cancer Research, National Cancer Institute and NIH Clinical Center (N/A)
- Harold Amos Physician-Scientist Development Program Award (N/A)
- Alex’s Lemonade Stand Center of Excellence (N/A)
- California Institute of Regenerative Medicine, UCSF Alpha Clinic Physician Scientist Research Fellowship Award (N/A)
- UCSF Medical Scientist Training Program (T32GM141323)
- Contrato Río Hortega by the Instituto de Salud Carlos III (CM24/00094)
- TERAV+ by RICORS/TERAV (RD24/0014/0003)
- Baszucki Lymphoma Therapeutics Initiative (N/A)
- Dept. of Defense Congressionally Directed Medical Research Program Award (W81XWH2210807)
- American Society of Hematology Research Training Award for Fellows (N/A)
- UCSF Helen Diller Family Comprehensive Cancer Center Preclinical Therapeutic Core Facility (P30CA082103)
- Chan Zuckerberg Biohub Physician-Scientist Fellowship Program (N/A)
- National Institute of Health (ZIA BC 011823)
- UCSF Living Therapeutics Initiative (N/A)
- American Society of Transplantation and Cellular Therapy New Investigator Award (N/A)
- Multiple Myeloma Research Foundation Translational Accelerator Award (N/A)
- NIH (T32AI007529)
This publication has 38 references indexed in Scilit:
- Alternative target recognition elements for chimeric antigen receptor (CAR) T cells: beyond standard antibody fragmentsCytotherapy, 2024
- Low-affinity CAR T cells exhibit reduced trogocytosis, preventing rapid antigen loss, and increasing CAR T cell expansionLeukemia, 2022
- Non-cleavable hinge enhances avidity and expansion of CAR-T cells for acute myeloid leukemiaCancer Cell, 2022
- Tuning the ignition of CAR: optimizing the affinity of scFv to improve CAR-T therapyCellular and Molecular Life Sciences, 2021
- DNA methyltransferase inhibitors upregulate CD38 protein expression and enhance daratumumab efficacy in multiple myelomaLeukemia, 2019
- CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapyNature Medicine, 2017
- The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in MiceCancer Cell, 2016
- Chimeric Antigen Receptors With Mutated IgG4 Fc Spacer Avoid Fc Receptor Binding and Improve T Cell Persistence and Antitumor EfficacyMolecular Therapy, 2015
- Characterization of CD22 expression in acute lymphoblastic leukemiaPediatric Blood & Cancer, 2015
- The HADDOCK web server for data-driven biomolecular dockingNature Protocols, 2010